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OBJECTIVES In this study we determined whether 13N-ammonia uptake measured late after injection
provides additional insight into myocardial viability beyond its value as a myocardial blood
flow tracer.
BACKGROUND Myocardial accumulation of 13N-ammonia is dependent on both regional blood flow and
metabolic trapping.
METHODS Twenty-six patients with chronic coronary artery disease and left ventricular dysfunction
underwent prerevascularization 13N-ammonia and 18F-deoxyglucose (FDG) positron emis-
sion tomography, and thallium single-photon emission computed tomography. Pre- and
postrevascularization wall-motion abnormalities were assessed using gated cardiac magnetic
resonance imaging or gated radionuclide angiography.
RESULTS Wall motion improved in 61 of 107 (57%) initially asynergic regions and remained abnormal
in 46 after revascularization. Mean absolute myocardial blood flow was significantly higher in
regions that improved compared to regions that did not improve after revascularization
(0.63 6 0.27 vs. 0.52 6 0.25 ml/min/g, p , 0.04). Similarly, the magnitude of late
13N-ammonia uptake and FDG uptake was significantly higher in regions that improved
(90 6 20% and 94 6 25%, respectively) compared to regions that did not improve after
revascularization (67 6 24% and 71 6 25%, p , 0.001 for both, respectively). However, late
13N-ammonia uptake was a significantly better predictor of functional improvement after
revascularization (area under the receiver operating characteristic [ROC] curve 5 0.79) when
compared to absolute blood flow (area under the ROC curve 5 0.63, p , 0.05). In addition,
there was a linear relationship between late 13N-ammonia uptake and FDG uptake (r 5 0.68,
p , 0.001) as well as thallium uptake (r 5 0.76, p , 0.001) in all asynergic regions.
CONCLUSIONS These data suggest that beyond its value as a perfusion tracer, late 13N-ammonia uptake
provides useful information regarding functional recovery after revascularization. The parallel
relationship among 13N-ammonia, FDG, and thallium uptake supports the concept that
uptake of 13N-ammonia as measured from the late images may provide important insight
regarding cell membrane integrity and myocardial viability. (J Am Coll Cardiol 1999;33:
678–86) © 1999 by the American College of Cardiology
Accurate distinction between potentially reversible (viable
myocardium) and irreversible (nonviable myocardium) re-
gional dysfunction (1,2) has important implications regard-
ing decisions for coronary artery revascularization and risk
stratification in patients with chronic coronary artery disease
and left ventricular dysfunction. Evaluation of myocardial
viability with positron emission tomography (PET) usually
involves assessment of resting myocardial blood flow and
metabolic activity, using two separate tracers. The suitability
of ammonia as a myocardial perfusion imaging agent has
been established in experimental animal models (3–5) and
in human subjects (6–10). Absolute quantitation of blood
flow (ml/min/g) is achieved using two- or three-
compartment kinetic models (7,8). However, whether met-
abolic trapping of ammonia can identify myocardial viability
in patients with coronary artery disease and left ventricular
dysfunction has not been well established.
The interplay between blood flow and metabolism in the
extraction and retention of 13N-ammonia is complex. The
early extraction phase of freely diffusible 13N-ammonia
reflects blood flow while the later, slow turnover phase
reflects metabolic trapping of 13N-ammonia. Although the
exact mechanism of 13N-ammonia transport across the
myocardial membrane has not been conclusively established,
it has been suggested that 13N-ammonia may cross cell
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membranes by diffusion (11) or by the active sodium-
potassium transport mechanism (12) influenced by the
concentration gradient across the cell membrane (13). Once
in the myocyte, myocardial retention of 13N-ammonia
involves predominantly the conversion of 13N-ammonia and
glutamic acid to 13N-labeled glutamine mediated by aden-
osine triphosphate (ATP) and glutamine synthetase
(4,13,14). Thus, the extent of 13N-ammonia metabolism
may depend on the ATP state of the myocyte. Beyond
metabolic trapping by glutamine synthetase, other studies
have shown that the extraction of 13N-ammonia by myo-
cardial cells is also influenced by cell membrane integrity,
intracellular-extracellular pH gradient, and possibly an an-
ion exchange system for bicarbonate (15).
Intracellular levels of 13N-ammonia may reflect cellular
processes dependent on viable myocardium. Thus, we hy-
pothesized that 13N-ammonia uptake measured from the
last 10 to 15 min of image acquisition may provide infor-
mation regarding myocardial viability beyond absolute
blood flow (ml/min/g) measured during the first 2.7 to
3.0 min after 13N-ammonia injection, using a two-
compartment model. Accordingly, we examined the mag-
nitude of absolute blood flow, late 13N-ammonia uptake and
18F-deoxyglucose (FDG) metabolism in patients with
chronic coronary artery disease and left ventricular dysfunc-
tion undergoing revascularization.
METHODS
Patient selection. Twenty-six patients (23 men, 3 women)
with angiographically proven coronary artery disease, rang-
ing in age from 42 to 76 years (mean 59 6 10 years)
underwent prerevascularization 13N-ammonia and FDG
PET, and stress-redistribution-reinjection thallium single-
photon emission computed tomography (SPECT) studies.
In addition, all patients underwent pre- and postrevascular-
ization radionuclide angiography, and 16 of the 26 patients
underwent gated cardiac magnetic resonance imaging
(MRI).
Left ventricular ejection fraction by radionuclide angiog-
raphy before revascularization ranged from 16% to 45%
(mean 31 6 8%) at rest. Coronary angiography demon-
strated significant stenosis (70% reduction in luminal diam-
eter) of all three major epicardial arteries in 12 patients, of
two coronary arteries in 8 patients, and of one coronary
artery in 6 patients. Eighteen patients had at least one
totally occluded epicardial coronary artery.
The time intervals between prerevascularization studies
were 3 6 3 days between PET and MRI, 12 6 16 days
between PET and radionuclide angiography, and 20 6 42
days between PET and thallium imaging. Postrevascular-
ization tests were performed 2.5 6 0.8 months after
coronary angioplasty and 5.8 6 8.8 months after coronary
artery bypass grafting. No patient had unstable angina,
myocardial infarction or congestive heart failure during the
follow-up period.
Sixteen patients underwent coronary artery bypass graft-
ing and 10 patients had percutaneous transluminal coronary
angioplasty. All three major coronary arteries were revascu-
larized in 12 patients, two vessels in 4 patients, and one
vessel in 10 patients. Informed written consent was obtained
from each patient, and the Institutional Review Board on
human research approved the study protocol.
Positron emission tomography. The first 11 patients had
their PET studies performed on a Posicam whole-body
camera (Positron Corp.; 21 contiguous slices spaced 5.1 mm
apart), and 15 patients had their PET studies performed on
an Advance (General Electric) whole-body camera (35 slices
spaced 4.25 mm apart). The in-plane reconstructed resolu-
tion for both cameras was approximately 6.5 mm.
All PET studies were performed after an overnight fast.
Prior to scanning, plasma glucose ranged from 65 to
115 mg/dl (mean 5 91 6 13 mg/dl) in the nondiabetic
patients, and 135 to 243 mg/dl (mean 5 198 6 49) in five
diabetic patients. Approximately 1 h before the FDG study,
all patients received 50 g of oral glucose. During imaging,
plasma glucose levels were measured in 20 of the 21
nondiabetic patients (mean glucose level 5 131 6
41 mg/dl), and in 4 of the 5 diabetic patients (mean glucose
level 5 198 6 110 mg/dl). The FDG images were of
acceptable quality in one (the patient received insulin during
imaging) of the five diabetic patients. The patient was
positioned, an attenuation scan performed, and a 30-s
continuous infusion of approximately 5 to 15 mCi 13N-
ammonia was administered intravenously. A period of
$50 min was allowed between 13N-ammonia and FDG
injections for 13N-ammonia decay (Fig. 1). After 13N-
ammonia injection, 16 to 20 dynamic frames (12 3 20 s,
1 3 60 s, 3 3 300 s, or 12 3 5 s, 3 3 20 s, 3 3 60 s and
2 3 300 s) were acquired in 15 to 20 min. The PET
imaging was performed with septa out (“3D mode”) for
patients receiving 5 mCi and with septa in (“2D mode”) for
patients receiving 15 mCi of 13N-ammonia. Scatter correc-
tion was performed for both 2D and 3D acquisition. Chest
phantom measurements (with cardiac and lung inserts)
indicated that our average 3D myocardial values of nCi/cc
differed from the 2D values by less than 3%. Static images
of 13N-ammonia were generated from data beginning at
5 min after 13N-ammonia injection, corresponding to the
Abbreviations and Acronyms
ATP 5 adenosine triphosphate
FDG 5 18F-deoxyglucose
METs 5 metabolic equivalents
MRI 5 magnetic resonance imaging
PET 5 positron emission tomography
ROC 5 receiver operating characteristic
SD 5 standard deviation
SPECT 5 single-photon emission computed
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final 10 to 15 min of data acquisition. Static FDG images
were generated from data corresponding to the final 30 to
45 min of data acquisition (Fig. 1). All images were
reconstructed perpendicular to the long axis of the body to
create a series of transaxial tomograms.
Thallium SPECT imaging. All patients underwent stress-
redistribution-reinjection thallium SPECT as previously
described (16). Imaging was performed with a three-headed
camera (Triad, Trionix, Twinsburg, Ohio). The SPECT in
plane and z-axis resolution was approximately 14.5 mm.
Thallium images were reconstructed as a series of whole-
body transaxial tomograms.
Magnetic resonance imaging. Pre- and postrevasculariza-
tion electrocardiogram (ECG) gated MRI was performed
using a 0.5 T magnet (Picker) in 6 patients and a 1.5 T
magnet (Signa, General Electric) in 10 patients, as previ-
ously described (17). A 15–20-min scan allowed for acqui-
sition of four to five slices at four to five time points in the
cardiac cycle from end-diastole to end-systole using spin-
echo imaging (echo time, 20 ms; repetition time 5 R
wave-to-R wave time, with two excitations). Each slice was
10 mm thick, with a center-to-center slice distance of
20 mm. Immediately after this acquisition, a second acqui-
sition was begun, (again, four to five time points at four to
five slices), to fill the gaps between slices. Thus, the final
image sequence consisted of 8 to 10 contiguous transaxial
slices (10 mm thickness, 10 mm center-to-center interslice
distance) at four or five time points in the cardiac cycle from
end-diastole to end-systole. Total imaging time was 30 to
45 min.
Gated equilibrium radionuclide angiography. Gated
equilibrium radionuclide angiography (in the supine posi-
tion) was performed at rest in all 26 patients and during
symptom-limited bicycle exercise in 24 patients, using a
conventional Anger camera. Red blood cells were labeled in
vivo with approximately 25 mCi of technetium-99m per-
technetate. Time-activity curves were generated, from
which the left ventricular ejection fraction was computed as
previously described (18). The lower limit of normal left
ventricular ejection fraction at rest using this technique is
45% for our laboratory, with a reproducibility of 4%.
Data analysis. To objectively compare relative regional
thallium, FDG and 13N-ammonia uptake, five myocardial
regions of interest were drawn on each visually selected
FDG and 13N-ammonia tomogram and on each corre-
sponding thallium stress, redistribution and reinjection to-
mogram as previously described (17). The PET, SPECT,
and MRI slices had different slice thickness and different
interslice distance (4.25 to 5.1 mm for PET, 6.88 mm for
SPECT thallium, and 10 mm for MRI). Therefore, we
performed a weighted resumming of the PET and SPECT
images in order to match the MRI slice thickness. An
average of approximately three midventricular MRI slices
per patient were each divided into five regions of interest,
which visually matched the regions drawn on the thallium
SPECT, FDG, and 13N-ammonia PET images. Because
each region encompassed a relatively large amount of
myocardial tissue, it is unlikely that minor differences in
visual matching among the five regions would alter the
results appreciably.
In 10 of the 26 patients, pre- and postrevascularization
wall motion was assessed visually by gated radionuclide
angiography. In these subjects, it was necessary to determine
the correspondence between the regional abnormalities
found on the planar gated radionuclide angiography and the
transaxial PET and thallium tomograms. To accomplish
this, five regions were drawn on one midventricular PET
and thallium slice per patient and then reprojected on the
radionuclide angiography image with the best septal left
anterior oblique view.
REGIONAL MYOCARDIAL THALLIUM, FDG, AND 13N-
AMMONIA UPTAKE. The myocardial region on the thallium,
FDG, and 13N-ammonia series that corresponded to the
region with the highest thallium uptake on the thallium
stress image series was used as the reference region for
computing relative thallium, FDG, and 13N-ammonia up-
take. Thallium, FDG, and 13N-ammonia uptake in all other
Figure 1. Sequence and timing of 13N-ammonia and FDG PET imaging.
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myocardial regions was expressed as a percent of the activity
in this reference region.
Regional data may be influenced by neighboring regions
and are not completely independent. We tried to minimize
these effects by making the regions fairly large (five per slice,
with 10-mm-thick slices). Furthermore, to quantify this
dependence we measured, using actual regions from this
study, the cross-talk from one region to the next, by blurring
the sectors (with one sector set to 100 and the others set to
0) with a 6.5-mm filter (equal to the in-plane resolution of
the scanner). We found the cross-talk between neighboring
sectors to be about 4% (i.e., at most, about 4% of the activity
from one region appears in a neighboring region) and
between nonadjacent sectors to be less than 1%. In the
z-axis (where the slices are combined to 10 mm thickness)
a similar analysis led to a spillover of 10.1% from a sector in
one slice to the same sector in an adjacent slice.
REGIONAL MYOCARDIAL BLOOD FLOW. Absolute regional
myocardial blood flow was computed from the dynamic
13N-ammonia data using a two-compartment model similar
to that described by Kuhle et al. (8). Although this method
is widely used, so too is the three-compartment model,
which uses a longer data acquisition. The two methods, we
have found, correlate quite well (3 compartment 5 2
compartment 3 1.14 1 0.03, r-value 5 0.95), giving
essentially the same result apart from a scale factor of 1.14
and a small offset. The myocardial time activity curves for
13N-ammonia were generated from the first 8 to 16 dynamic
frames (corresponding to the first 2.7 to 3.0 min after
13N-ammonia injection). Our model accounts for spillover
but does not correct for partial volume effects.
ANALYSIS OF REGIONAL FUNCTION. In 16 of the 26 pa-
tients, assessment of regional systolic wall thickening was
done visually using transaxial end-diastolic and end-systolic
MRI images. The PET slice that best matched the corre-
sponding MRI slice was selected visually, using both the
PET attenuation images (which show the lung outlines, the
heart shadow, and the slice in which the liver first begins to
appear) and the PET emission images. Regions were
assessed as normal or asynergic (hypokinetic or akinetic) by
two observers, blinded to the PET data, using the movie
display of superimposed MRI end-diastolic and end-systolic
images. In 10 of the 26 patients, assessment of regional
systolic wall motion was performed visually with planar
gated radionuclide angiography using the cine-loop display
of frames in the best septal left anterior oblique view during
one cardiac cycle. Differences were resolved by consensus.
To avoid the problem of postoperative paradoxical septal
motion, wall thickening was used for the classification of
wall motion in the 16 patients with MRI studies. Among
the 10 patients with radionuclide angiography, 7 had
coronary artery bypass surgery and 3 had percutaneous
transluminal coronary angioplasty. None of the patients
exhibited new septal wall-motion abnormalities postopera-
tively. Myocardial regions with impaired wall motion before
revascularization were studied again after revascularization
and classified as having reversible or irreversible left ventric-
ular dysfunction. A region was considered to be reversible if
regional contraction improved from akinetic to hypokinetic
or normalized after revascularization.
Statistical analysis. Data are presented as mean 6 SD. For
comparison of differences, two-tailed Student t test for
paired (pre- and postrevascularization rate-pressure product,
metabolic equivalents (METs), and ejection fraction) and
unpaired samples (blood flow and tracer uptake in reversible
and irreversible asynergic regions) were applied. Receiver
operating characteristic (ROC) curves were used to compare
the abilities of absolute blood flow and late 13N-ammonia
uptake to predict regions that would recover function after
revascularization. Myocardial regions were not completely
independent. This limited dependence was determined as
described earlier in the Methods section.
RESULTS
Clinical and functional outcome postrevascularization.
Of the 26 patients studied, 19 (73%) had symptoms of
angina before revascularization. After revascularization, only
2 of 19 patients had persistent angina. Mean rate-pressure
product among the 24 patients who underwent treadmill
exercise increased from 20.4 6 5.5 mm Hgzbpmz103 before
to 26.1 6 5.6 mm Hgzbpmz103 after revascularization (p ,
0.001). Mean METs achieved during exercise increased
from 6.0 6 2.7 before to 8.4 6 3.1 after revascularization
(p , 0.001). After revascularization, mean left ventricular
ejection fraction increased during exercise (from 29 6 10%
to 37 6 13%, p , 0.001) and at rest (from 31 6 8% to 35 6
11%, p , 0.003). Thirteen of the 26 patients (50%) showed
$4% increase in left ventricular ejection fraction at rest from
31 6 8% before to 41 6 11% after revascularization, of
whom 5 (38%) showed further increase in left ventricular
ejection fraction (by $4% ejection fraction units) from 45 6
12% at rest to 52 6 13% during exercise after revascular-
ization.
Analysis of regional function. A total of 197 revascular-
ized regions were analyzed in 26 patients. Wall motion was
normal in 90 (46%) regions before revascularization and
abnormal in 107 (54%) regions. After revascularization, wall
motion improved in 61 of the 107 asynergic regions (57%)
and did not improve in 46 (43%) regions.
13N-Ammonia absolute myocardial blood flow in relation
to functional outcome after revascularization. Mean ab-
solute myocardial blood flow in the 90 regions with normal
prerevascularization wall motion was 0.64 6 0.24 ml/min/g
using the two-compartment model (0.76 ml/min/g if a
three-compartment model had been used). Absolute myo-
cardial blood flow could not be measured in four regions of
one patient owing to poor statistics and in three other
regions because the fit of the data to the model did not
converge.
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Wall motion improved in 61 of 107 (57%) asynergic
regions studied with 13N-ammonia. Of the 107 asynergic
regions studied, 4 had to be excluded because the fit of the
data to the model did not converge. Before revasculariza-
tion, mean regional blood flow was significantly higher in
the asynergic regions that improved after revascularization
(0.63 6 0.27 ml/min/g) compared to the regions that did
not improve after revascularization (0.52 6 0.25 ml/min/g,
p , 0.04, Fig. 2). Positive and negative predictive accuracies
for improvement of asynergic regions after revascularization
at various absolute blood flow threshold values are shown in
Figure 3. The data suggest that a blood flow value of
0.3 ml/min/g would correctly predict 62% of asynergic
regions that improved after revascularization and 65% of
regions that remained dysfunctional after revascularization.
A threshold value of 0.7 ml/min/g shows a positive predic-
tive value of 70% but a fairly low negative predictive value of
49%. There was poor correlation between the magnitude of
absolute 13N-ammonia blood flow and FDG uptake in the
subset of asynergic regions (r 5 0.27, p 5 0.008).
Relation between tracer uptake and functional outcome
after revascularization.
13N-AMMONIA UPTAKE. Among the 90 regions with normal
prerevascularization wall motion, mean 13N-ammonia up-
take was 95 6 18%. Among the 107 asynergic regions,
mean regional 13N-ammonia uptake was significantly
higher in the 61 asynergic regions that improved after
revascularization (90 6 20%) compared to the 46 regions
that did not improve after revascularization (67 6 24%, p ,
0.001, Fig. 2). Positive and negative predictive accuracies for
improvement of asynergic regions after revascularization at
various 13N-ammonia uptake threshold values are shown in
Figure 3. The data suggest that 40% 13N-ammonia thresh-
old value would correctly predict 60% of asynergic regions
Figure 2. Plots of mean 13N-ammonia absolute myocardial blood
flow, late 13N-ammonia uptake, and FDG uptake in asynergic
regions that improved (open bars) and those that did not improve
(solid bars) after revascularization are shown. Absolute myocardial
blood flow, late 13N-ammonia uptake, and FDG uptake are
significantly higher in reversible compared to irreversible asynergic
regions after revascularization.
Figure 3. Positive and negative predictive values in assessing
recovery of asynergic regions after revascularization are shown in
relation to the magnitude of absolute blood flow, late 13N-
ammonia uptake, FDG uptake, and thallium uptake (maximum on
either redistribution or reinjection). When 13N-ammonia uptake
and FDG metabolic data were combined, none of the asynergic
regions demonstrating uptake of less than 50% on both 13N-
ammonia and FDG images showed improvement in systolic wall
thickening after revascularization (negative predictive accuracy of
100%).
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that improved after revascularization and 100% of regions
that remained dysfunctional after revascularization. When
70% 13N-ammonia threshold value was used, the positive
predictive accuracy of 13N-ammonia uptake for recovery of
regional systolic function increased to 71% but the negative
predictive accuracy decreased to 71%.
Receiver operating characteristic (ROC) curves were used
to compare the abilities of absolute blood flow and 13N-
ammonia uptake to predict regions that would recover
function after revascularization. The 13N-ammonia uptake
was a significantly better predictor of recovery of function
after revascularization than absolute blood flow (area under
the ROC curve 5 0.79 and 0.63, respectively, p , 0.05, Fig.
4). In addition, there was a linear relationship between
13N-ammonia uptake and FDG uptake among all regions
studied (r 5 0.64, p , 0.001). This linear relationship
between 13N-ammonia uptake and FDG uptake persisted in
the subgroup of asynergic regions (r 5 0.68, p , 0.001, as
shown in Fig. 5) and among asynergic regions that did not
improve after revascularization (r 5 0.75, p , 0.001). A
patient example with concordant 13N-ammonia uptake and
FDG uptake is shown in Figure 6.
FDG UPTAKE. The FDG uptake was measured in 86 of the
90 regions with normal prerevascularization systolic wall
motion; mean FDG uptake was 95 6 21%. Of the 107
regions identified as asynergic before revascularization, 61
improved and 46 remained abnormal after revascularization.
Mean FDG uptake (measured in 60 of the 61) was
significantly higher in the asynergic regions that improved
after revascularization (94 6 25%) compared to the regions
(measured in 37 of 46) that did not improve after revascu-
larization (71 6 25%, p , 0.001) (Fig. 2). Positive and
negative predictive accuracies for improvement of asynergic
regions after revascularization at various FDG threshold
values are shown in Figure 3. The data suggest that 40%
FDG threshold value would correctly predict 65% of asyn-
ergic regions that improved after revascularization and 100%
of regions that remained dysfunctional after revasculariza-
tion. When 70% FDG threshold value was used, the
positive predictive accuracy of FDG for recovery of regional
systolic function increased to 76%, but the negative predic-
tive accuracy decreased to 68%. When 13N-ammonia uptake
and FDG metabolic data were combined, at 65% FDG
threshold value, the positive and negative predictive accu-
racies for improvement of asynergic regions after revascu-
larization were 78% and 82%, respectively. None of the
eight asynergic regions demonstrating uptake of less than
50% on both 13N-ammonia and FDG images showed
improvement in systolic wall thickening after revasculariza-
tion (negative predictive accuracy of 100%). Thus, FDG
imaging adds incrementally to late 13N-ammonia imaging
with regard to differentiation of reversible from irreversible
left ventricular dysfunction after revascularization.
THALLIUM UPTAKE. Because uptake of thallium by myocar-
dial cells depends on cell membrane integrity, and hence
viability, we also examined whether a relationship exists
between the potassium analogue thallium and late 13N-
ammonia uptake. Mean thallium activity in the 61 asynergic
regions that improved after revascularization was 82 6 15%
on redistribution images and 84 6 16% on reinjection
images. In contrast, mean thallium activity in the 46
Figure 4. Plots of ROC curves for late 13N-ammonia uptake and
absolute blood flow to predict functional improvement after
revascularization in asynergic regions. Area under the ROC curve
for absolute blood flow and late 13N-ammonia uptake is displayed.
Late 13N-ammonia uptake was a significantly better predictor of
functional improvement when compared to absolute blood flow.
Figure 5. Relation between percent late 13N-ammonia uptake and
FDG uptake (top) and thallium uptake on redistribution imaging
(bottom) in reversible (open circles) and irreversible (closed
circles) asynergic regions after revascularization. There is a linear
relationship among late 13N-ammonia uptake, FDG uptake, and
thallium uptake in all asynergic regions.
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asynergic regions that did not improve after revasculariza-
tion was 63 6 21% on redistribution images and 67 6 23%
on reinjection images (p , 0.001 for both). In addition,
there was a linear relationship between 13N-ammonia and
thallium uptake on redistribution (r 5 0.76, p , 0.001) and
reinjection imaging (r 5 0.72, p , 0.001) among all
asynergic regions studied (Fig. 5).
DISCUSSION
We examined whether 13N-ammonia uptake measured
from the static images late after injection provides additional
insight into myocardial viability beyond its value as a
myocardial blood flow tracer. Mean absolute blood flow and
late 13N-ammonia uptake were significantly higher in asyn-
ergic regions that improved compared to those that did not
improve after revascularization. However, late 13N-
ammonia uptake was found to be significantly better than
absolute blood flow as a predictor of functional improve-
ment after revascularization. In addition, there was a linear
relationship among late 13N-ammonia uptake, FDG up-
take, and thallium uptake in all asynergic regions.
Absolute myocardial blood flow and functional outcome
after revascularization. The observed difference in mean
absolute myocardial blood flow between asynergic regions
showing reversible (0.63 6 0.27 ml/min/g) versus irrevers-
ible (0.52 6 0.25 ml/min/g, p , 0.04) dysfunction after
revascularization is rather small, with a considerable overlap.
The overlapping ranges of absolute blood flow values may
relate to the variability of blood flow, which is inherently
larger than the variability of tracer uptake. Two factors
contribute to this increased variability: first, the model for
flow must extract several independent parameters from the
data, and second, the blood flow information comes primar-
ily from the early dynamic data, which have higher variabil-
ity than do the data for relative uptake values. This larger
variability combined with the limited number of measure-
ments could conceivably have masked larger differences in
blood flow between reversible and irreversible regions. In
addition, subjective alignment of PET and MRI slices could
have presumably be off by a few millimeters, thereby
introducing some variability in the results.
The large variability in blood flow measurements is not
unique to our laboratory. Previous studies in normal subjects
have reported a coefficient of variation of 12% and 21% in
regional 13N-ammonia myocardial blood flow at rest
(19,20). Thus, the substantial variation of myocardial blood
flow in normal subjects may make it difficult to detect true
differences in resting myocardial blood flow among patients
with chronic coronary artery disease and left ventricular
dysfunction.
Late 13N-ammonia uptake for myocardial viability as-
sessment. In experimental animals, several investigators
have shown that the myocardial extraction and retention of
13N-ammonia are related not only to regional blood flow
but also to myocardial oxygenation and metabolism
(3,4,15). Under hypoxic or ischemic conditions, the reduc-
tion of intracellular ATP to concentrations in the range of
the Km for the enzyme-ATP complex could reduce intra-
cellular 13N-ammonia metabolism by glutamine synthetase.
In an isolated perfused rabbit heart model of similar blood
flow but disparate oxygenation, a significant reduction in
myocardial extraction of 13N-ammonia was observed in the
poorly oxygenated hearts (4). In patients with coronary
artery disease, the kinetics of 13N-ammonia have been
shown to differ between viable myocardium and scar, and
this could provide a method for myocardial viability deter-
mination independent of FDG data (21). In patients with
chronic coronary artery disease and left ventricular dysfunc-
tion, it is not known whether chronic regional hypoperfu-
sion and hypoxia influence retention of 13N-ammonia,
independently of the magnitude of blood flow itself.
Our findings indicate that late 13N-ammonia uptake was
significantly higher in the asynergic regions that improved
after revascularization (90 6 20%) compared to the regions
that did not improve after revascularization (67 6 24%, p ,
0.001). Percent mean late 13N-ammonia uptake was quite
similar to the percent mean FDG uptake. Mean FDG
uptake was significantly higher in the asynergic regions that
improved after revascularization (94 6 25%) compared to
the regions that did not improve after revascularization
(71 6 25%, p , 0.001). Furthermore, there was a linear
relationship between 13N-ammonia and FDG uptake
Figure 6. Concordance between 13N-ammonia and FDG uptake
is demonstrated in this patient example. Matched transaxial
tomograms are displayed for 13N-ammonia uptake and FDG
uptake by PET, with corresponding end-diastolic and end-systolic
MRI tomograms before (pre-) revascularization (on the left) and
after (post-) revascularization (on the right). On the PET study,
both 13N-ammonia and FDG uptake are severely reduced in the
apical region (matched defect). Corresponding MRI tomograms
reveal absent systolic wall thickening in the apical region before
revascularization, which remains irreversible after revascularization.
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among all regions studied (r 5 0.64, p , 0.001), as well as
in the subgroup of asynergic regions (r 5 0.68, p , 0.001).
Similar results were obtained by Gould et al. (22) using
rubidium-82. Among patients with evolving myocardial
infarction, loss of cell membrane integrity for trapping the
potassium analogue rubidium-82 paralleled abnormal intra-
cellular metabolism assessed by FDG. Our data show a
linear relationship between cell membrane dysfunction (as-
sessed by the potassium analogue thallium) and impairment
of metabolic trapping of 13N-ammonia (assessed by late
13N-ammonia uptake). Once in the myocardium, the fac-
tors that affect redistribution of thallium include 1) the
severity of the initial defect; 2) the presence of viable
myocytes (23,24); 3) the concentration of the tracer in the
blood; and 4) the rate of decline of thallium levels in the
blood (25,26). The incremental value of thallium reinjection
after stress-redistribution imaging has been addressed in
prior publications (16,27).
Metabolic viability and functional recovery after revas-
cularization. Although there are a number of publications
in the literature to suggest that the presence of preserved
tracer uptake is indicative of viable myocardium capable of
improving function after revascularization, this observation
is not uniform (28,29). The observed discrepancies between
functional recovery and metabolic activity with PET may
reflect the underlying alterations in cellular metabolism,
histomorphology, and function (30,31). In our study, con-
siderable overlap existed between reversible and irreversible
asynergic regions in the intermediate zone of mild–
moderate tracer uptake for predicting recovery of contractile
function. The asynergy in a region with mild–moderate
reduction in tracer uptake may be due to repetitive stunning
and/or hibernation or nontransmural infarction with a
mixture of viable and scarred myocardium. Asynergy arising
from repetitive stunning and/or hibernation may be revers-
ible.
Conversely, asynergy arising from nontransmural in-
farction may be irreversible after revascularization (32).
Even in the absence of nontransmural infarction, cellular
de-differentiation and slippage of myofibrillar units as a
consequence of chronic hypoperfusion may result in
reduced or absent contractile recovery after revasculariza-
tion, or may require longer time for recovery of contrac-
tile elements before improvement in contractile function
is observed (33).
Conclusions. In patients with chronic coronary artery dis-
ease and left ventricular dysfunction, late 13N-ammonia
uptake provides useful information regarding functional
recovery after revascularization beyond its value as a perfu-
sion tracer. The parallel relationship among 13N-ammonia,
FDG, and thallium uptake supports the concept that uptake
of 13N-ammonia as measured from the late images may
provide important insight regarding cell membrane integrity
and myocardial viability.
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